glp-1 drugs names types of glp 1 Receptor Agonists: An Alternative for Rapid-Acting Insulin? The Future of Weight Loss:
Description
Pharm Res 2018;35:71
Since the approval of Wegovy for obesity in 2021 the obesity market has grown sevenfold to $24bn in 2023[3]
Theoretically, tirzepatide offers the best anti-cancer effects, considering the potential link between weight loss and reduced cancer risk
Participants were required to have a BMI between 28 and 38 kg/m 2 , to have an HbA1c concentration between 6.5 and 9%
